pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
PUBLIC COMPANY
save

$ARWRARROWHEAD PHARMACEUTICALS, INC.

$ARWR59.90-0.98%
Pasadena, CA, USupdated 17d ago

Arrowhead Pharmaceuticals, Inc. is a publicly traded biopharmaceutical company based in Pasadena, California. Arrowhead's products in development act through RNA interference (RNAi) mechanisms of action. The company focuses on treatments for hepatitis B, liver disease associated with alpha 1-antitrypsin deficiency and cardiovascular disease.

Website ↗SEC EDGAR ↗Yahoo Finance ↗
community read0 votes
pipeline
4
marketed
1
phase 3
1
catalysts ytd
2
approvals ytd
0
recalls ytd
0

Pipeline(4)

pipeline depth4 products
Phase 2: 1Phase 3: 1Marketed: 1Unknown: 1
1Phase 21Phase 31Marketed1Unknown
Marketed
plozasiran sodium
Hypertriglyceridemia
Phase 3
fazirsiran sodium
Alpha-1 Antitrypsin Deficiency (A1AD)
Phase 2
zodasiran sodium
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia)
drug
REDEMPLO
1 INDICATIONS AND USAGE REDEMPLO is indicated as an adjun…

📅 Upcoming

no upcoming catalysts on record

🕒 Recent(90d)

nothing in the last 90 days
view all catalysts →

Active trials

  • phase3Study of Zodasiran in Adolescent Participants With Homozygous Familial Hypercholesterolemiarecruitingn=10
  • phase3Phase 3 Study of Plozasiran in Adults With Hypertriglyceridemiacompletedn=1,456
  • phase2Study of ARO-DIMERPA in Adult Participants With Mixed Hyperlipidemiarecruitingn=78
  • phase1A First-In-Human Study of ARO-033 in Adult Participantsrecruitingn=42
  • phase3A Phase 3 Study of Zodasiran in Adolescent and Adult Subjects With Homozygous Familial Hypercholesterolemia (YOSEMITE)recruitingn=60
  • phase2A First-In-Human Study of ARO-INHBE in Adults With Obesity With and Without Type 2 Diabetes Mellitusrecruitingn=180
  • phase2Study of ARO-MAPT-SC in Healthy Subjects and Subjects With Early Alzheimer's Diseaserecruitingn=112
  • phase2Study of Plozasiran (ARO-APOC3) in Adults With Mixed Dyslipidemiacompletedn=353
🐶 Hiring Signal
No open roles indexed yet — view ARROWHEAD PHARMACEUTICALS, INC. jobs →

News

  • Arrowhead’s Ionis problem, Kyverna’s next-gen end and more biotech earnings
    When Ionis Pharmaceuticals’ Tryngolza undersold, investors immediately looked to Arrowhead Pharmaceuticals’ executives for answers on how they will navigate a launch in the same market.
    biospace · 3d ago
  • Arrowhead’s blood-brain barrier tech is ‘arguably better’ than others, analysts say after data drop
    Arrowhead Pharmaceuticals’ siRNA candidate achieved “compelling” tau reductions in an early study of healthy volunteers, with a magnitude of effect that seems to outperformother blood-brain barrier…
    biospace · 1mo ago
  • Roche expands obesity R&D footprint with Rona deal worth $1B+
    Roche has gained access to a genetic obesity approach from China's Rona Therapeutics for up to $100 million in upfront and near-term payments.
    biospace · 1mo ago
  • Roche inks $1.2B deal with China's Rona to enter emerging ALK7 obesity race
    Roche has committed $100 million in upfront and near-term payments to license Rona Therapeutics’ ALK7 drug candidate, joining Alnylam, Arrowhead, GSK and Novo Nordisk in an emerging obesity niche.
    fiercebiotech · 1mo ago
  • Arrowhead's new Redemplo findings in severe hypertriglyceridemia have analysts split
    Safety and dosing are likely to be “key differentiators” for Arrowhead Pharmaceuticals as it looks to challenge Ionis Pharmaceuticals’ lead in the severe hypertriglyceridemia market.
    biospace · 2mo ago
  • Epicrispr lands $90M to advance epigenetic editing drug for rare muscle disease
    The startup has completed enrollment of an early-stage study testing a first-of-its-kind treatment for facioscapulohumeral muscular dystrophy, a disease targeted by many other drugmakers.
    biopharma_dive · 3mo ago
  • ‘Significant’ demand for Revolution drug; Intellia pinpoints liver toxicity culprit
    Early indicators from a compassionate use plan led analysts to hike projections for daraxonrasib. Elsewhere, Intellia believes it’s answered a key safety question and Arrowhead moved to catch a rival.
    biopharma_dive · 3mo ago
  • Biotechs bring big launches and pharma rivalries into Q2 earnings period
    With the second quarter earnings period underway, BioSpace examines five biotechs with meaningful catalysts that analysts and investors are watching.
    biospace · 3mo ago
  • Arrowhead puts pressure on Ionis with positive data for triglyceride lowering drug
    With Phase 3 data showing what analysts called a “potentially best-in-class profile,” Arrowhead Pharmaceuticals plans to submit for FDA approval of plozasiran by the end of the year—hoping to follo…
    biospace · 3mo ago
view all news mentions →
identifiers
ticker
$ARWR
SEC CIK
0000879407
country
US
source
sec_tickers
mentioned in
9news items
entity-linker matched
Data sources
SEC EDGAR · openFDA
last refreshed 21m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?